A novel modified tissue-type plasminogen activator (t-PA), E6010, gradually increases coronary blood flow after thrombolysis compared with native t-PA, urokinase and balloon catheter occlusion-reperfusion.
In a canine copper coil-induced coronary thrombosis model, the differences in frequency of reperfusion arrhythmias (premature ventricular complexes: PVC) and mortality rate after thrombolysis by intravenous bolus injection of a novel modified tissue-type plasminogen activator (t-PA), E6010, and by continuous intravenous infusion of native t-PA or urokinase were evaluated. Rapid coronary occlusion and reperfusion were produced with a balloon catheter in another group of dogs, and the findings were compared with those in the thrombolysis groups. Reperfusion occurred gradually after the administration of E6010, but was significantly more rapid after administration of native t-PA and urokinase (P < 0.05). PVC were observed more frequently in native t-PA, urokinase and balloon occlusion-reperfusion groups than in the E6010 group. The mortality rate due to ventricular fibrillation was 0.0% in the E6010 group, 50.0% in the native t-PA and balloon occlusion-reperfusion groups, and 33.3% in the urokinase group. These results suggest that the more gradual reperfusion of the coronary artery at an earlier period after drug administration led to the lower frequency of reperfusion arrhythmias and low mortality rate in the E6010 group than in the native t-PA, urokinase and balloon occlusion-reperfusion groups.
Saito
M
M
Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan.
Suzuki
S
S
Yui
Y
Y
Kawai
C
C
D000818:Animals; D005117:Cardiac Complexes, Premature / Q000503:physiopathology; D002404:Catheterization; D003326:Coronary Circulation / Q000187:drug effects*; D003328:Coronary Thrombosis / Q000503:physiopathology; D004285:Dogs; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D005260:Female; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D008297:Male; D015428:Myocardial Reperfusion Injury / Q000503:physiopathology*; D010959:Tissue Plasminogen Activator / Q000494:pharmacology*; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology*; D014693:Ventricular Fibrillation / Q000503:physiopathology
D005343:Fibrinolytic Agents; C076356:E 6010; D004815:Epidermal Growth Factor; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator